About Pionyr Immunotherapeutics

Pionyr Immunotherapeutics is a clinical stage company developing cancer immunotherapies that target the tumor microenvironment to enhance the body’s antitumor immunity. The company’s approach, Myeloid Tuning™, is designed to enhance the immune system’s anti-tumor response by altering, or “tuning”, the myeloid infiltrate of the tumor microenvironment with high specificity and for very specific purposes.

The company was founded in 2015 by Max Krummel, Ph.D., a professor at University of California, San Francisco School of Medicine (UCSF), who has been making significant strides in immuno-oncology since the mid-1990s. Dr. Krummel is the co-inventor of YERVOY® (ipilimumab), the first checkpoint inhibitor, which was approved in 2011 to treat melanoma. Pionyr has exclusively licensed technology from UCSF based on Dr. Krummel’s work.

In 2020, Pionyr entered a transformational alliance with Gilead Sciences (read more) ahead of receiving IND clearance for its two lead programs PY314 and PY159.

Pionyr’s Path


Pionyr Founded


$1.3M Series A Funding


$8M Series A-1 OrbiMed, SV, Osage, Mission Bay


4 TME-Targeted mABs in Process


18 Employees


Located at MBC BioLabs


$69M Series B NEA, Sofinnova, Vida, Trinitas + Prior Investors


New Labs at Genesis Towers, 40+ Employees


Pionyr/Gilead Alliance


PY314 and PY159 into P1



Pionyr/Lonza Partnership

Pionyr's Third Program



55+ Employees


Steven P. James photo

Steven P. James / President and CEO

Kevin Baker PhD photo

Kevin Baker, PhD / Senior Vice President and Chief Development Officer

Tony Brew photo

Tony Brew / Senior Director, Information Technology

Marc Chamberlain photo

Marc Chamberlain, MD / Senior Medical Director

Larry Garrido photo

Larry Garrido / Senior Director, Facilities Operations

Evan Greger photo

Evan Greger, MBA, MSc / Senior Vice President and Chief Technical Officer

Lynnae Jackson photo

Lynnae Jackson, MBA / Senior Director, Clinical Operations

Irina Kasatkina photo

Irina Kasatkina, MSc / Vice President, Quality

Alicia Levey, PhD photo

Alicia Levey, PhD / Senior Vice President, Chief Business Officer and Head of Portfolio Strategy

Yunfeng Li photo

Yunfeng Li, PhD / Senior Director, Biostatistics

Linda Liang Photo

Linda Liang, PhD / Vice President, Protein Sciences

Isabel Luther photo

Isabel Luther / Senior Director, Clinical Operations

Monte Montgomery photo

Monte Montgomery / Senior Vice President and Chief Financial Officer

Leonard Reyno photo

Leonard Reyno, MD / Senior Vice President and Chief Medical Officer

Lisa Stemmerich photo

Lisa Stemmerich, MBA / Vice President, Human Resources

Board of Directors

Rishi Gupta, JD / OrbiMed

Steven P. James / President and CEO, Pionyr Immunotherapeutics

Regina Salvat, PhD / Sofinnova

William Grossman, MD, Phd / SVP, Oncology Clinical Development & Therapeutic Area Head, Gilead Sciences

Mike Ross, PhD / SV Health Investors

Scientific Advisory Board

Chloe Atreya, MD, PhD / Assistant Clinical Professor, Department of Medicine, UCSF

Miriam Merad, MD, PhD / Professor of Oncological Science, Medicine and Immunology and a member of the Immunology Institute and The Tisch Cancer Institute, Mount Sinai School of Medicine

Stephen Hodi, MD / Director of the Melanoma Center and the Center for Immuno-Oncology, Dana-Farber Cancer Institute


gilead logo

nea logo

orbimed logo

sofinnova logo

sv health investors logo

vida ventures logo

osage logo

mission bay capital logo

trinitas capital logo


gilead logo

ProBiogen logo

celonic logo

celonic logo

celonic logo